Are you a penny stock trader looking for some cheapies? Look no further than medical device maker, Aethlon Medical Inc. (OTC:AEMD), to play PR bingo with. The support has long been there for AEMD stock at around to 0.06 level and Thursday’s announcement of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) is just the ticket needed. The old adage of buy on rumor, sell on news could be the set up for a perfect play if the opportunity arises where the PPS comes down just enough to make it playable.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
AEMD Stock Chart
Market Cap: 11.77M
Last: 0.075 ▼ -0.005 (-6.25%)
Dollar Volume: $8,286
Issued and Outstanding: 156,956,675
14-Day Rel Strength: 53.09%
14-Day Stochastic: 60.00%
Looking for Hot Penny Stocks?
Click here and get Our Penny Stock Picks FREE
At present, cash flow for Aethlon Medical is present, but limited. Their limited revenues have stemmed from their deal with the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, founded in 1958 by former President of the U.S. Dwight D. Eisenhower, which responsible for the development of new technologies for use by the military. Conducting a research project to build devices to reduce the incidence of sepsis in combat-injured soldiers is both heroic and “A” listable since not every schmo with a tool box can do something like this.
The filing for FDA approval for the Company’s Hemopurifier® is the play here on AEMD stock. The device targets the rapid clearance of infectious viral pathogens and immunosuppressive proteins from the entire circulatory system. Assuming approval is given, persons suffering from the Hepatitis C virus will be enrolled in U.S. studies at three of the top renal care facilities, including the Beth Israel Medical Center in New York City.
This brings us to AEMD stock and where it stands. Although the 52 week low was set almost a year ago, support has been strong at around the $0.065 level even though the shares traded in the $0.06 to $0.062 range at the close of 2012. Considering that there were 18,333,294 stock options exercisable at September 30, 2012 between $0.076 – $0.41, its a clear indicator of where insiders can get more shares of AEMD stock at. A play on this new IDE submission to the FDA with a “buy and hold” strategy could open the doors for a PPS jump just like back in February, 2012 when it hit $0.1799.
About AEMD Stock
Aethlon Medical, Inc. is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. Click here to view the SEC filings for AEMD.
Last 5 Trading Sessions:
Bottom Line: AEMD is firmly locked in on our penny stocks picks list with the huge potential behind it for a PR play. Anywhere south of $0.07, north of $0.06 would appear to be the best positioning to consider it cheap. even at its current price, AEMD stock offers a good chance for a 50% or better PR Bingo play, assuming they get approval from the FDA. Those chances increased in our eyes based on their milestone achievement funding with DARPA.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share